Chimerix commences Phase 3 trial of brincidofovir

Chimerix (CMRX) initiates dosing in a Phase 3 study of the oral nucleotide analog lipid-conjugate brincidofovir in patients with cytomegalovirus infection.

Existing antiviral therapies for the infection (which affects hematopoietic cell transplant recipients) carry the risk of "significant hematologic and renal toxicities."

No approved therapy for the prevention of the infection in hematopoietic cell transplant recipients exists. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs